Debu Tripathy
#128,859
Most Influential Person Now
Researcher
Debu Tripathy's AcademicInfluence.com Rankings
Debu Tripathycomputer-science Degrees
Computer Science
#5560
World Rank
#5871
Historical Rank
Data Mining
#109
World Rank
#109
Historical Rank
Algorithms
#193
World Rank
#196
Historical Rank
Computational Linguistics
#807
World Rank
#820
Historical Rank
Download Badge
Computer Science
Debu Tripathy's Degrees
- PhD Computer Science Stanford University
- Bachelors Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Debu Tripathy Influential?
(Suggest an Edit or Addition)Debu Tripathy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2002) (3080)
- Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. (1999) (2850)
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996) (1402)
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998) (1107)
- Circulating Tumor Cells in Patients with Breast Cancer Dormancy (2004) (873)
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu (1992) (643)
- HER-2 gene amplification can be acquired as breast cancer progresses. (2004) (560)
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. (2019) (527)
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (2018) (518)
- Tamoxifen for early breast cancer: An overview of the randomised trials (1999) (494)
- Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment (2017) (429)
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. (2016) (422)
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2011) (318)
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. (2012) (317)
- Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies (2004) (317)
- Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. (1999) (309)
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER (2011) (296)
- Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. (2004) (291)
- Image-detected breast cancer: state of the art diagnosis and treatment. (2005) (277)
- MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. (2005) (265)
- Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. (2004) (251)
- Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. (2004) (248)
- Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. (2001) (228)
- Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. (2014) (214)
- First-Line Herceptin® Monotherapy in Metastatic Breast Cancer (2001) (207)
- CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers (2017) (191)
- Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer (2004) (185)
- First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. (2001) (179)
- Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. (2018) (171)
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) (164)
- uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues (2006) (161)
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer (2001) (155)
- Adaptive Randomization of Neratinib in Early Breast Cancer. (2016) (152)
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer (2017) (142)
- Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review (2017) (141)
- Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. (2009) (136)
- Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2 (2011) (135)
- Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors (2017) (133)
- Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial (2018) (129)
- Adjuvant chemotherapy in Older Women with Early-Stage Breast Cancer (2010) (121)
- Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. (2007) (119)
- HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer (2016) (116)
- Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
- Putting cancer pain management regimens into practice at home. (2002) (104)
- Traditional Chinese medicine in the treatment of breast cancer. (2002) (96)
- Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). (2016) (96)
- Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer (2017) (95)
- The PRO-SELF pain control program improves patients' knowledge of cancer pain management. (2004) (94)
- Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. (2015) (92)
- Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer (2007) (92)
- Managing metastatic bone pain: the role of bisphosphonates. (2007) (86)
- Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. (2020) (85)
- A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer (2010) (83)
- Complementary and alternative medicine in early-stage breast cancer. (2001) (83)
- Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. (2004) (83)
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer (2015) (82)
- Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. (2002) (79)
- Integrative Oncology Practice Guidelines. (2007) (78)
- Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients (2016) (77)
- Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy (2019) (75)
- The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management (2007) (72)
- Blood oxygenation level‐dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: A pilot study (2013) (72)
- Multidisciplinary Care for Breast Cancer: Barriers and Solutions (2003) (71)
- The usefulness of a daily pain management diary for outpatients with cancer-related pain. (2002) (70)
- T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. (2016) (66)
- Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity (2017) (64)
- The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management. (2003) (63)
- Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial (2018) (63)
- RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer (2016) (61)
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer (2014) (61)
- c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun (2017) (60)
- Pain Management Autobiographies and Reluctance to Use Opioids for Cancer Pain Management (2002) (60)
- Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313) (2017) (58)
- Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer (2019) (58)
- IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation* (2005) (57)
- First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. (2013) (56)
- Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study (2011) (54)
- Aromatase inhibitors: rationale and use in breast cancer. (2005) (53)
- Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods (2014) (51)
- Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. (2005) (51)
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer (2018) (50)
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. (2019) (50)
- Radiologist's role in breast cancer staging: providing key information for clinicians. (2014) (50)
- Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial (2018) (48)
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. (2018) (48)
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER (2014) (48)
- Opposing Effects of Runx2 and Estradiol on Breast Cancer Cell Proliferation: In Vitro Identification of Reciprocally Regulated Gene Signature Related to Clinical Letrozole Responsiveness (2011) (46)
- Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. (1992) (46)
- Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process (2018) (45)
- Expression profiling of circulating tumor cells in metastatic breast cancer (2014) (45)
- Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs (2018) (45)
- No evidence for sex differences in the severity and treatment of cancer pain. (2004) (43)
- Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. (2011) (42)
- Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. (2018) (41)
- IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. (2005) (41)
- DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes (2017) (41)
- A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors (2017) (41)
- Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. (2020) (40)
- Qualitative research contribution to a randomized clinical trial. (2005) (39)
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study (2009) (39)
- Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer (2013) (39)
- Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? (2014) (39)
- Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer (2017) (39)
- Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. (2006) (38)
- Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data (2017) (37)
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. (2020) (37)
- Co-targeting estrogen receptor and HER2 pathways in breast cancer. (2014) (37)
- Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy (2019) (37)
- The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea (2019) (36)
- Efficacy of radiotherapy for ovarian ablation (2004) (35)
- Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. (2004) (35)
- Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. (2007) (35)
- RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer (2018) (34)
- Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer: A Randomized Clinical Trial (2019) (34)
- Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density (2015) (34)
- First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. (2001) (33)
- Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. (2005) (32)
- Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience (2016) (32)
- Functional consequence of the MET-T1010I polymorphism in breast cancer (2014) (32)
- Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes (2016) (32)
- Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. (2015) (31)
- Molecular markers for breast cancer diagnosis, prognosis and targeted therapy (2015) (31)
- Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. (2017) (31)
- Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil (2006) (31)
- Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer (2017) (30)
- CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer (2018) (29)
- Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. (2020) (29)
- EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low (2015) (29)
- Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) (2012) (29)
- Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer (2021) (29)
- Prolactin-Induced Protein (PIP) Regulates Proliferation of Luminal A Type Breast Cancer Cells in an Estrogen-Independent Manner (2013) (28)
- Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. (2019) (28)
- Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer (2012) (28)
- Survival Impact of Integrative Cancer Care in Advanced Metastatic Breast Cancer (2009) (27)
- Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression (2017) (26)
- Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. (2011) (26)
- Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer (2006) (26)
- Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) (2020) (26)
- Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. (2002) (26)
- Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. (2004) (25)
- Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer (2005) (25)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (25)
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial (2021) (25)
- Risk factors for falls in older patients with cancer (2017) (24)
- Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. (2019) (23)
- Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long‐term Breast Cancer Survivors (2017) (23)
- Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials (2013) (22)
- Mammographic breast density is associated with the development of contralateral breast cancer (2017) (22)
- Growth factors and their receptors. (1994) (22)
- De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. (2020) (22)
- Outcomes in patients with early‐stage breast cancer who underwent a 21‐gene expression assay (2017) (21)
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial (2021) (21)
- Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy (2015) (20)
- Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial (2017) (20)
- EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer (2017) (20)
- Androgen receptor expression on circulating tumor cells in metastatic breast cancer (2017) (20)
- Overview: gemcitabine as single-agent therapy for advanced breast cancer. (2002) (20)
- Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis (2018) (20)
- EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. (2017) (20)
- EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy (2020) (19)
- Clinical outcomes based on multigene profiling in metastatic breast cancer patients (2016) (19)
- Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy (2017) (18)
- Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer (2021) (18)
- Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain during participation in a psychoeducational intervention study to improve pain management. (2011) (18)
- Targeted Therapies in Breast Cancer (2005) (18)
- Aerobic and Resistance Exercise Improves Shoulder Function in Women Who Are Overweight or Obese and Have Breast Cancer: Randomized, Controlled Trial. (2019) (17)
- Malnutrition and overall survival in older patients with cancer. (2018) (17)
- Overall survival in older patients with cancer (2018) (17)
- Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). (2015) (17)
- Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC). (2016) (16)
- Beyond Anatomic Staging: Are We Ready to Take the Leap to Molecular Classification? (2005) (16)
- Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (2021) (16)
- Bisphosphonates in oncology: breast cancer and beyond. (2001) (15)
- Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. (2012) (15)
- Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells (2021) (15)
- Neurocognitive deficits in older patients with cancer. (2018) (15)
- Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital. (2015) (15)
- Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs (2019) (15)
- Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer (2021) (15)
- A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment (2019) (15)
- Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation (2017) (14)
- Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. (2016) (14)
- Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience (2018) (14)
- Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer (2020) (14)
- Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis (2018) (14)
- Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. (2008) (13)
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (2020) (13)
- Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk (2021) (13)
- Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases (2015) (13)
- Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. (2019) (13)
- Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion (2019) (12)
- Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1) (2019) (12)
- Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer (2018) (12)
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. (2021) (12)
- Breast cancer risk in relation to plasma metabolites among Hispanic and African American women (2019) (12)
- Malignancy rates after surgical excision of discordant breast biopsies. (2015) (12)
- De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry (2019) (12)
- Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer (2019) (12)
- ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. (2019) (12)
- Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy (2016) (11)
- Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes (2017) (11)
- Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. (2009) (11)
- Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. (2018) (11)
- Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise on physical fitness and quality-of-life in breast cancer survivors (2020) (11)
- Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population (2019) (11)
- Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. (2018) (11)
- Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib (2021) (10)
- Phenotypic and proteomic alterations of acquired trastuzumab resistance (2005) (10)
- HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. (2019) (10)
- Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (2019) (10)
- Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer (2022) (10)
- registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer (2005) (10)
- Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7. (2015) (10)
- Invasive lobular carcinoma: an understudied emergent subtype of breast cancer (2022) (10)
- Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative (2015) (9)
- Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes (2018) (9)
- Neoadjuvant Pertuzumab‐containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER‐2/neu‐positive Breast Cancer: A Retrospective, Single Institution Experience (2018) (9)
- Adoption, Acceptability, and Accuracy of an Online Clinical Trial Matching Website for Breast Cancer (2012) (9)
- NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer (2020) (9)
- The PRO-SELF©: Pain Control Program— An Effective Approach for Cancer Pain Management (2014) (9)
- Gemcitabine in breast cancer: future directions. (2002) (9)
- Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. (2022) (9)
- Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer (2016) (9)
- Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience (2020) (8)
- First-Line Treatment with Bevacizumab and Paclitaxel Prolongs Progression-Free Survival in Metastatic Breast Cancer (2005) (8)
- Development of CNS metastases and survival in patients with inflammatory breast cancer (2018) (8)
- Abstract P3-07-14: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study (2015) (8)
- Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer (2014) (7)
- The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 (2016) (7)
- Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. (2020) (7)
- Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. (2021) (7)
- How long should adjuvant tamoxifen be continued? (1994) (7)
- Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study (2022) (7)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (7)
- Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer (2018) (7)
- A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents (2012) (7)
- Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance (2015) (7)
- Targeting metabolic adaptations in the breast cancer–liver metastatic niche using dietary approaches to improve endocrine therapy efficacy (2021) (7)
- POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. (2020) (7)
- Faculty Opinions recommendation of Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. (2006) (6)
- Point-counterpoint: soy intake for breast cancer patients. (2002) (6)
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. (2010) (6)
- Blood oxygen level dependent (BOLD) contrast MRI and breast cancer chemotherapy response. (2006) (6)
- Abstract P2-11-03: Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial (2017) (6)
- Abstract PD2-01: Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL (2019) (6)
- Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial (2019) (6)
- Traditional Chinese medicine in the treatment of breast cancer (Part one) (2002) (6)
- Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (2015) (6)
- Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy (2001) (6)
- Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. (2015) (6)
- Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial (2008) (6)
- Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer. (2004) (6)
- Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis (2020) (6)
- 2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC (2007) (6)
- Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. (2017) (6)
- PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening (2021) (6)
- Awareness, concern, and communication between physicians and patients on bone health in cancer (2014) (5)
- Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways (2007) (5)
- Negative Is Positive: A Plea to Publish All Studies Regardless of Outcome (2015) (5)
- Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer (2018) (5)
- Implications of Omitting Radiation After Breast Conserving Surgery in Elderly Women With Low-risk Invasive Breast Cancer (2012) (5)
- Aerobic and resistance exercise improves Reynolds risk score in overweight or obese breast cancer survivors (2020) (5)
- Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer (2022) (5)
- Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer (2015) (5)
- 3-49 Adjuvant Docetaxel or Vinorelbine With or Without Trastuzumab for Breast Cancer (2006) (5)
- The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival (2022) (5)
- A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. (2022) (5)
- Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations (2021) (5)
- Navigator program for breast cancer trial recruitment and enrollment at a county hospital (2005) (5)
- Time to begin adjuvant chemotherapy and survival in breast cancer patients: A retrospective observational study using latent class analysis (2014) (5)
- Effect of cardiac dysfunction on treatment outcome in the herceptin pivotal trial (2001) (5)
- Mechanism of Action and Clinical Impact of Ribociclib—Response (2017) (5)
- Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2- advanced breast cancer (ABC). (2019) (5)
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (2020) (5)
- Aerobic and Resistance Exercise Improve Patient-reported Sleep Quality and is Associated with Cardiometabolic Biomarkers in Hispanic and Non-Hispanic Breast Cancer Survivors who are Overweight or Obese: Results from a Secondary Analysis. (2021) (5)
- Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis (2019) (4)
- Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors (2017) (4)
- Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. (2022) (4)
- Oral daily ibandronate: An effective and convenient therapy for skeletal complications in metastatic breast cancer (2004) (4)
- Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study (2022) (4)
- 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7 (2020) (4)
- Protein Pathway Activation Mapping for Multi-Omic Based Precision Medicine (2016) (4)
- Abstract 5780: E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells (2018) (4)
- In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. (2019) (4)
- Effects of a 16-week Resistance and Aerobic Exercise Intervention on Metabolic Syndrome in Overweight/Obese Latina Breast Cancer Survivors (2015) (4)
- The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer (2019) (4)
- Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL (2019) (4)
- A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer (2007) (4)
- How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist. (2018) (4)
- Abstract PD2-08: Ribociclib with endocrine therapy for premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7 trial (2019) (4)
- HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-D (2015) (4)
- Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. (2018) (4)
- Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial (2001) (4)
- Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. (2016) (4)
- Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer (2021) (4)
- MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. (2022) (4)
- What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer (2019) (4)
- Abstract P5-21-15: The synergistic antitumor activity of entinostat (MS-275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative breast cancer (2018) (4)
- A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores (2021) (4)
- Abstract PD10-03: Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings (2020) (4)
- HER2 status and breast cancer therapy: recent advances (2009) (4)
- Abstract 4492: Humanized anti-EGFR antibody panitumumab inhibits tumor growth of inflammatory breast cancer by inducing antitumor immunity (2019) (4)
- Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer (2022) (4)
- Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay. (2016) (4)
- Biological Therapy of Breast Cancer (2012) (4)
- Clinical findings and outcomes of MRI staging of breast cancer in a diverse population (2018) (4)
- Long-term safety of oral ibandronate in patients with skeletal metastases from breast cancer: 4-year follow-up data (2004) (4)
- CBP / β-Catenin / FOXM 1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer (2018) (4)
- The incidence and impact of brain metastasis in patients with hereditary BRCA1/2 mutated invasive breast cancer in a prospectively followed cohort. (2020) (3)
- Ribociclib and Endocrine Therapy in Breast Cancer. Reply. (2019) (3)
- Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer (2021) (3)
- Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). (2021) (3)
- Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489) (2017) (3)
- Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study (2018) (3)
- Integrative oncology — strong science is needed for better patient care (2015) (3)
- Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype (2020) (3)
- Are we hitting the right combination for hormonally sensitive breast cancer? (2009) (3)
- Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer. (2012) (3)
- Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial (2022) (3)
- Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations. (2022) (3)
- Dietary Fat Reduction Improves Relapse-Free Survival in Postmenopausal Women Previously Treated for Early-Stage Breast Cancer: Results from a Phase III Women's Intervention Nutrition Study (2005) (3)
- Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. (2018) (3)
- Prognostic significance of geriatric assessment. (2017) (3)
- Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. (2018) (3)
- Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. (2023) (3)
- Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry (2021) (3)
- Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS (2019) (3)
- EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer (2022) (3)
- Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations (2020) (3)
- 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) (3)
- Abstract P5-14-03: Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: Phase II CONTROL trial (2020) (3)
- HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. (2019) (3)
- Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population. (2018) (2)
- Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice (2020) (2)
- Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. (2021) (2)
- Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastu (2016) (2)
- The Challenges of Randomized Trials in Integrative Cancer Care (2004) (2)
- Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy (2017) (2)
- Value of routine staging imaging studies for patients with stage III breast cancer (2016) (2)
- Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. (2020) (2)
- [18F]FMAU for PET imaging in breast cancer patients. (2015) (2)
- New threshold of ER positivity in early stage HER2- breast cancer. (2016) (2)
- Efficacy of Very-Low-Dose Capecitabine in Metastatic Breast Cancer (2015) (2)
- Focus on Research Methods Qualitative Research Contribution to a Randomized Clinical Trial (2005) (2)
- Systemic Therapy for Advanced Breast Cancer (2004) (2)
- Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis (2020) (2)
- Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC) (2019) (2)
- Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial (2018) (2)
- Abstract P3-09-12: Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory breast cancer (mIBC) and non-IBC triple negative breast cancer (mTNBC) (2020) (2)
- Abstract 1549: Molecular profiling of circulating tumor cells as a surrogate for distant metastasis in stage IV breast cancer (2016) (2)
- Metabolic syndrome and breast cancer: Effects of a 16-week combined exercise intervention. (2013) (2)
- How are quality of life and work productivity associated with living longer with HER2+ metastatic breast cancer? (2017) (2)
- Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). (2017) (2)
- Abstract P1-16-02: Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis (2018) (2)
- registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2007) (2)
- The Impact of Postmastectomy Radiation Therapy in Intermediate-Risk Breast Cancer Patients With Limited Axillary Disease (2013) (2)
- registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2016) (2)
- Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study. (2018) (2)
- 349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) (2)
- 93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) (2021) (2)
- Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer (2020) (2)
- Breast carcinoma en cuirasse as a natural progression of untreated breast cancer (2015) (2)
- Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting. (2013) (2)
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023) (2)
- Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. (2019) (2)
- Abstract P5-03-04: Targeting the tumor microenvironment by CXCR4 inhibition to abrogate trastuzumab resistance in HER2-positive breast cancer (2019) (2)
- Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer (2021) (2)
- Meeting Highlights2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, December 2006 (2007) (2)
- Abstract P5-08-08: Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR– HER2+ disease from the SystHERs registry (2017) (2)
- The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care (2015) (2)
- Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers (2020) (2)
- Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer (2020) (2)
- A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer | PER (2015) (2)
- Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study (2018) (2)
- Abstract 1505: Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition (2015) (1)
- Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer (2017) (1)
- Abstract P4-13-11: Everolimus, letrozole and trastuzumab in estrogen receptor and HER2-positive patients with metastatic breast cancer and other solid tumors: Evaluating synergy and overcoming resistance (2016) (1)
- Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (2015) (1)
- Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies (2022) (1)
- Abstract 1776: Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple-negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313) (2017) (1)
- ePoster SessionsLong-Term Results of a Prospective Pilot Safety and Feasibility Study of Adjuvant Concurrent Capecitabine and External Beam Irradiation Demonstrates Tolerability and Efficacy in High-Risk Locally Advanced Breast Cancer (2017) (1)
- Biologically targeted therapy: as good as advertized? (2003) (1)
- Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists. (2018) (1)
- Individual attributions of living longer with HER2+ metastatic breast cancer: Findings from a community web-based survey. (2014) (1)
- Abstract P3-10-23: Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab (2019) (1)
- Abstract P5-16-01: Documenting and sharing breast cancer knowledge from National Cancer Institute designated comprehensive cancer centers (NCI-CCCs) with community oncologists (2018) (1)
- 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 2006 (2007) (1)
- Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease (2016) (1)
- Abstract P5-11-03: Practice patterns and outcomes of post progression treatment after CDK 4/6 inhibitors (2020) (1)
- Abstract OT3-02-05: NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC) (2017) (1)
- Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases-Reply. (2022) (1)
- Understanding palbociclib practice patterns in a real-world setting. (2019) (1)
- Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer (2022) (1)
- The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). (2021) (1)
- Abstract 1078: TGF-β and TNF-α activate gene transcription programs associated with poor breast cancer prognosis (2015) (1)
- Abstract LB-165: Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data (2017) (1)
- Abstract OT1-04-08: Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine (2017) (1)
- Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing (2022) (1)
- A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score. (2019) (1)
- Abstract P6-17-01: Central nervous system metastases at diagnosis in patients with HER2+ MBC: Baseline characteristics, HER2-targeted treatments and clinical outcomes from the SystHERs registry (2016) (1)
- Patient-reported outcomes (PROs) from the systemic therapies for HER2-positive metastatic breast cancer (MBC) registry study (SystHERs): Eliciting the patient experience. (2014) (1)
- Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC). (2021) (1)
- Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). (2021) (1)
- Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases (2021) (1)
- Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression (2021) (1)
- 320TiPA phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC (2017) (1)
- Clinical findings and outcomes from MRI staging of breast cancers in women. (2012) (1)
- Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS) (2020) (1)
- Impact of neoadjuvant chemotherapy to surgery interval on survival outcomes in breast cancer patients. (2015) (1)
- HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 (2016) (1)
- Abstract 1971: Inhibition of CXCR4 pathway augments trastuzumab sensitivity in HER2 positive breast cancer cells with intrinsic and acquired trastuzumab resistance (2014) (1)
- 448 Alleviation of bone pain with oral and intravenous ibandronate in women with metastatic breast cancer (2003) (1)
- The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (2020) (1)
- Abstract P5-08-04: LMP7-specific inhibitor M3258 modulates the tumor microenvironment of aggressive breast cancer (2022) (1)
- Diagnosis and management of early stage breast cancer. (1995) (1)
- A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer (2008) (1)
- Modified Bi‐Rads Scoring of Breast Imaging Findings Improves Clinical Judgment (2015) (1)
- Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL (2019) (1)
- Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple‐Negative Breast Cancer (2022) (1)
- Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases (2021) (1)
- Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS. (2021) (1)
- Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy (2019) (1)
- Abstract P5-04-02: The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation (2016) (1)
- Chemotherapy and hormonal therapy for breast cancer. (1993) (1)
- Abstract PS4-05: Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC) (2021) (1)
- Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC). (2012) (1)
- Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in an underserved population. (2011) (1)
- Abstract 496: Androgen receptor expression on circulating tumor cells in metastatic breast cancer (2016) (1)
- Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy (2019) (1)
- Abstract OT2-1-01: Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Ini (2015) (1)
- PARP inhibitors: the story is still unfolding. (2011) (1)
- Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
- Erratum: IκB kinase α regulates subcellular distribution and turnover of cyclin D1 by phosphorylation (Journal of Biological Chemistry (2005) 280 (33945-33952)) (2005) (1)
- An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies (2005) (1)
- Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis. (2018) (1)
- Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies (2022) (1)
- Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial (2019) (1)
- The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC). (2020) (1)
- Toxicity of Radiation Therapy Given Concomitantly with Palbociclib for Metastatic Breast Carcinoma (2019) (1)
- Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999-2012. (2015) (1)
- Abstract PD10-08: Remodeling the inflammatory breast cancer tumor microenvironment to enhance immunotherapy: Novel therapeutic development (2022) (1)
- Abstract CT011: Circulating tumor DNA (ctDNA) sequencing forHER2mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC) (2017) (1)
- Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab (2016) (1)
- Abstract OT1-03-04: INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC) (2019) (1)
- Breast Cancer Quality Care: What is at Stake? (2012) (1)
- Breast cancer advocacy in clinical care. (1998) (1)
- Integrative Medicine and Breast Cancer (2014) (1)
- Bridging the Care Gap Between Pediatric and Young Adult Cancer (2015) (1)
- FDA and Avastin: crossroads in an era of targeted therapies. (2010) (1)
- Overcoming Fundamental Challenges in Systemic Therapy for Breast Cancer (2009) (1)
- Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313 (2019) (1)
- 443 Safety and tolerability of oral ibandronate therapy in patients with metastatic bone disease (2003) (1)
- Phosphorylated ribosomal S6 (p-S6) as an indicator of HER2 signaling targeted drug resistance. (2013) (1)
- Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007. (2007) (1)
- Systemic adjuvant therapy for breast cancer (1992) (1)
- Intravenous and oral ibandronate reduce the risk of skeletal-related events (SREs) in patients with breast cancer and bone metastases (2004) (1)
- Abstract CT076: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (1)
- The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting. (2019) (1)
- 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007 (2007) (1)
- Validation of plasma metabolites associated with breast cancer risk among Mexican Americans. (2020) (1)
- Anthropometric Measurements and Cardiorespiratory Fitness in Breast Cancer Survivors: 2959 Board #24 June 3, 2: 00 PM - 3: 30 PM. (2016) (1)
- Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice (2020) (1)
- Abstract PD6-06: Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (1)
- Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008 (2008) (1)
- 462 Intravenous and oral ibandronate reduce the risk of skeletal related events in patients with metastatic bone disease (2003) (0)
- Abstract P3-01-05: Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS (2023) (0)
- A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment (2019) (0)
- Abstract 4736: ADAMs: potential biomarkers and oncotargets in breast cancer (2017) (0)
- Role of p53 mutations in clinical and pathological responses in an open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2-) breast cancer (BC) (2007) (0)
- Abstract P3-05-04: Impact of androgen receptor expression in fluoxymesterone-treated, estrogen receptor–positive metastatic breast cancer exposed to contemporary hormonal therapy (2017) (0)
- Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M. D. Anderson Cancer Center Experience (2007) (0)
- Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 2006 - Endocrine manipulation of early-stage, hormone-responsive breast cancer in premenopausal women (2007) (0)
- Antibody dependent cell-mediated cytotoxicity (adcc) of an anti-her2 antibody requires opsonization of tumor target (1996) (0)
- Complementary and alternative medicine in breast cancer: Models of research (2005) (0)
- Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance (2015) (0)
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer (2012) (0)
- Phase I/II Pilot Study to Assess Toxicity and Efficacy of Chinese Herbs to Treat Hot Flashed and Menopausal Symptoms for Women With a History of Breast Cancer (2001) (0)
- The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan, an anti-HER2 antibody-drug conjugate (2022) (0)
- Abstract 161: Long noncoding RNA subtype classification of human prostate adenocarcinomas (2015) (0)
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer (2005) (0)
- Abstract C44: Cancer staging and body mass index in Latina breast cancer survivors (2016) (0)
- Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 2006 - Bevacizumab combination regimens as first-line therapy of metastatic breast cancer: The NCCTG N0432 and XCALiBr trials (2007) (0)
- Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial (2008) (0)
- Abstract 2601: EphB4/EphrinB2 targeting increases the efficacy of cisplatin in triple negative breast cancer (2014) (0)
- Abstract P5-02-30: Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression (2023) (0)
- Abstract P2-09-08: Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer (2018) (0)
- Self-reported Upper Extremity Function, Active Range Of Motion And Shoulder Isometric Strength In Breast Cancer Survivors: 2798 Board #113 May 29, 3 (2015) (0)
- Evaluating the Neoadjuvant Treatment of Breast Cancer (2016) (0)
- Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment (2023) (0)
- Adjuvant Trastuzumab: Lessons Learned from Large Trials and Preliminary Results (2006) (0)
- Looking ahead to rational combinatorial therapy (2012) (0)
- Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women (2019) (0)
- Abstract 515: Single-cell transcriptomic analysis of HR+/HER2- breast cancer identifies gene signatures that predict outcomes of luminal A and B subtypes (2022) (0)
- Adjuvant Aromatase Inhibitors: Have We Defined the Optimal Regimen and Demonstrated a Survival Advantage? (2007) (0)
- Abstract P1-04-11: Recovery rates of circulating tumor cells in breast cancer cell lines spiked into peripheral blood (2013) (0)
- Abstract P5-08-04: Overexpression of CXCR-4 confers trastuzumab resistance in human breast cancer cell lines (2013) (0)
- Issue Information ‐ TOC (2020) (0)
- Abstract P1-16-04: Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis (2018) (0)
- Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI (2023) (0)
- Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction. (2022) (0)
- Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer (2019) (0)
- ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy (2022) (0)
- Abstract 392: Combined targeting of MET and PI3K improves efficacy in breast cancer models with concurrent MET/PI3K aberrations (2016) (0)
- Abstract 1798: Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib (2022) (0)
- Trends in rates of modified radical mastectomies and bilateral mastectomies in unilateral breast cancer. (2017) (0)
- A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. (2021) (0)
- Strategies to evaluate the clinical potential of botanical agents for breast cancer (2001) (0)
- Abstract OT2-2-06: Phase II single arm study of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy (2015) (0)
- Expression profiles can predict specific responses of capecitabine/docetaxel (C/D) based primary systemic therapy in breast cancer (BC) patients receiving neoadjuvant therapy (2007) (0)
- Co-Targeting HER2 and EphB4 Pathways (2013) (0)
- Abstract P5-08-14: Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer (2022) (0)
- 2060 POSTER An open-label study of neoadjuvant capecitabine (C) and docetaxel (D) with/without trastuzumab (T) to determine the role of p53 mutations in clinical and pathological responses in patients with recently diagnosed breast cancer (BC) (2007) (0)
- Making a difference in refractory breast cancer (2011) (0)
- Abstract P3-05-22: Serum S100A8/S100A9 levels are associated with increased risk of brain metastasis in patients with aggressive breast cancer (2023) (0)
- HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer (2016) (0)
- Association of body mass index with survival outcome in three breast cancer subtypes. (2015) (0)
- Abstract OT2-06-01: Breast Cancer Cohort of the Comprehensive Outcomes for After Cancer Health (COACH) Study: Study Protocol (2023) (0)
- Abstract P5-06-10: Validation of prognostic stage and anatomic stage in the American joint committee on cancer 8th edition for inflammatory breast cancer (2020) (0)
- Efficacy of low-dose capecitabine in metastatic breast cancer. (2012) (0)
- Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS (2019) (0)
- End-of-life health care utilization of gynecologic cancer patients at an urban, public hospital (2012) (0)
- registHER: Baseline characteristics of a cohort of HER2-positive metastatic breast cancer (MBC) patients. (2006) (0)
- Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) (2017) (0)
- Reply to A. Pfob and C. Sidey-Gibbons. (2022) (0)
- Faculty Opinions recommendation of Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. (2006) (0)
- Abstract 564: Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer (2018) (0)
- Abstract P6-09-35: Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors (2017) (0)
- Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS (2022) (0)
- Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial (2021) (0)
- Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis (2019) (0)
- Bone Densitometry and Fracture Risk in Breast Cancer (2016) (0)
- Abstract P1-14-07: Association between quantitative values of estrogen receptor expression level and pathological complete response in human epidermal growth factor 2-negative breast cancer: Should the clinical definition of triple-negative breast cancer be redefined? (2016) (0)
- Gene profiles of drug responsiveness in breast cancer cells. (2004) (0)
- Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. (2022) (0)
- Predictors of BRCA mutation in male breast cancer. (2015) (0)
- Abstract 3635: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy by modulating tumor microenvironment in aggressive breast cancers (2023) (0)
- Abstract P1-08-08: Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer viamathematical modeling and quantitative MRI (2022) (0)
- 116TiPMONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR + , HER2– advanced breast cancer (aBC) (2015) (0)
- Abstract B09: Association between cardiorespiratory fitness and quality of life in breast cancer survivors (2015) (0)
- Abstract 825: Identification of molecular therapeutic targets that enhance the antitumor activity of neratinib in breast cancer cells (2018) (0)
- Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool. (2023) (0)
- Abstract GS5-08: Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer (2023) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- Is ‘Maintenance Therapy’ in Metastatic Breast Cancer a Misnomer? (2010) (0)
- EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy. (2015) (0)
- Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. (2020) (0)
- Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer withPIK3CA/AKT1mutations (2019) (0)
- Abstract P5-17-06: Immune modulation with humanized anti-EGFR antibody panitumumab in an immunocompetent mouse model for inflammatory breast cancer (2019) (0)
- Abstract SS2-10: Impact of COVID-19 on study sites: Survey analysis from the noninterventional POLARIS study (2021) (0)
- New Serum Markers: More Data Needed (2008) (0)
- IκB kinase α regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. VOLUME 280 (2005) PAGES 33945-33952 (2005) (0)
- Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk (2021) (0)
- Abstract P3-03-06: Prediction of response to neoadjuvant systemic therapy in triple negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response (2022) (0)
- Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition (2020) (0)
- Dr. Debu Tripathy on Ribociclib Plus Hormone Therapy for Breast Cancer Patients (2019) (0)
- Abstract P2-06-22: PEA15-AA, an unphosphorylatable mutant of PEA15, as a novel therapeutic gene for triple-negative breast cancer (2019) (0)
- Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe (2015) (0)
- Abstract P3-08-02: Withdrawn (2019) (0)
- Abstract P4-06-04: Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies (2017) (0)
- Abstract P5-05-02: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study (2023) (0)
- Abstract P3-11-14: ONC201 synergistically induces cell death in triple negative breast cancer with CDK 4/6 and MEK inhibition (2020) (0)
- Predictive Biomarkers and Personalized Medicine Opposing Effects of Runx 2 and Estradiol on Breast Cancer Cell Proliferation : In Vitro Identi fi cation of Reciprocally Regulated Gene Signature Related to Clinical Letrozole Responsiveness (2012) (0)
- Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy (2019) (0)
- Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy (2019) (0)
- Toxicity of Concurrent Capecitabine and External Beam Irradiation in the Adjuvant Treatment of High Risk Breast Cancer: A Phase II Trial (2009) (0)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (0)
- The Best of 2008: Progress on Multiple Fronts (2008) (0)
- Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study (2022) (0)
- Abstract PD11-06: Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer (2022) (0)
- Abstract 1796: A targeted RNA-seq assay to measure activating ER mutations and ER/PR-associated gene expression predicts sensitivity to endocrine therapy for metastatic breast cancer (2017) (0)
- Abstract 1774: Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors (2022) (0)
- Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy (2019) (0)
- Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer. (2016) (0)
- Abstract P3-07-58: CD44v as a potential predictive biomarker for pathologic complete response in primary HER2+ breast cancer: Utility of adaptive response biopsy in preoperative therapy (2016) (0)
- Using neoadjuvant therapy for breast cancer in clinical practice: when and how? (2012) (0)
- Abstract P1-11-01: Effect of aerobic and resistance exercise on Reynolds risk score in overweight or obese breast cancer survivors (2020) (0)
- Abstract P4-17-02: Palbociclib in advanced male hormone positive breast cancer (2020) (0)
- Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL (2015) (0)
- 106P Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study (2021) (0)
- ASO Visual Abstract: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer (2022) (0)
- Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis (2019) (0)
- Prevalence of vitamin D insufficiency and falls in older cancer patients. (2017) (0)
- Debu Tripathy, MD, On the Future of Triple Negative Breast Cancer Treatment (2020) (0)
- Ribociclib and Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER-2) Breast Cancer: The Monaleesa Clinical Trials Program (2017) (0)
- Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Abstract PD6-07: Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (0)
- Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. (2017) (0)
- Abstract P1-08-03: Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers (2022) (0)
- Abstract C123: Ethnocentric differences in sarcopenic obesity and body composition in response to an aerobic and resistance exercise intervention for breast cancer survivors (2020) (0)
- Abstract P5-08-10: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy in aggressive breast cancer preclinical models (2022) (0)
- Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. (2015) (0)
- Highlights of the 2015 San Antonio Breast Cancer Symposium (2016) (0)
- Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
- Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor. (2022) (0)
- Abstract 548: Birinapant enhances gemcitabine's anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway-dependent apoptosis (2020) (0)
- Advances in Tumor Genetics (2016) (0)
- Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. (2020) (0)
- Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer (2021) (0)
- Abstract P1-05-03: JNK signaling regulates tumor cell–tumor-associated macrophage cross-talk in triple-negative breast cancer (2018) (0)
- Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines (2023) (0)
- Abstract 1409: Characterization of the LAR subtype triple negative breast cancer population (2019) (0)
- Abstract 3107: Identifying therapeutic vulnerabilities in HR-positive, HER2-negative advanced breast cancer patient-derived xenograft models refractory to CDK4/6 inhibition (2022) (0)
- Abstract P5-03-06: Overcoming MEK inhibitor resistance in triple-negative breast cancer by targeting myeloid cell leukemia-1 (MCL1), an anti-apoptotic protein (2019) (0)
- Abstract P1-18-29: Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study (2022) (0)
- Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). (2020) (0)
- Abstract P4-01-11: Clinical Findings and Outcomes from MRI Staging of Breast Cancer in a Diverse Population: (2012) (0)
- Abstract P3-05-04: Absence of Lobular Carcinoma In Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma (2023) (0)
- Treatment (tx) patterns and clinical outcomes for patients (pts) with de novo versus recurrent HER2+ metastatic breast cancer (MBC). (2013) (0)
- Abstract P3-05-38: Biology and clinical course of lobular cancer in breast cancer (BC) (2023) (0)
- Abstract PS7-19: Pre/perimenopausal (preMeno) women receiving palbociclib (PAL) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in a real-world setting: Treatment patterns from POLARIS (2021) (0)
- Impact of Aerobic and Resistance Exercise on Global Shoulder Function in Breast Cancer Survivors (2019) (0)
- Abstract 4294: Preclinical evaluation of imipridone ONC201 in triple negative breast cancer identifies predictive biomarkers and combinatorial opportunities (2017) (0)
- Clinical Testing of Supplementation Therapy in Early Stage Breast Cancer: Pitfalls and Opportunities (2003) (0)
- Title RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer (2018) (0)
- Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC). (2012) (0)
- Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer (2021) (0)
- Abstract 1395: Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer (2023) (0)
- Assessment of burden of illness in women with HER2+ metastatic breast cancer: Findings from a community web-based survey. (2011) (0)
- ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2018) (0)
- Advances in Clinical Oncology (2016) (0)
- P5-17-07: HER2+ Metastatic Breast Cancer Patient Experiences on Treatment in the Biologic Era: Findings from a Community Web-Based Survey. (2011) (0)
- Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer. (2011) (0)
- Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods (2014) (0)
- Abstract P3-07-10: The role of CBP/FOXM1 in triple negative breast cancer (2017) (0)
- Combination Therapy for Metastatic Melanoma (2016) (0)
- Implementing value-based cancer care: A multidisciplinary approach to defining breast cancer outcomes. (2016) (0)
- Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS (2023) (0)
- Molecular profiling of circulating tumor cells in non-metastatic breast cancer. (2015) (0)
- P3-14-21: Neoadjuvant Therapy Response, Subtype and BRCA Status in an Underserved Population. (2011) (0)
- Oncology Outpatients With Cancer-Related Pain Require More Than Around The Clock (ATC) Dosing Of Analgesics To Achieve Adequate Analgesia (2011) (0)
- Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer (2022) (0)
- Abstract A74: Metabolic syndrome in Latina breast cancer survivors after adjuvant chemotherapy (2016) (0)
- Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (2019) (0)
- 274PBaseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry (2017) (0)
- L a c k o f A d h e r e n c e W ith t he A nalgesic R egimen: A Significant B arrier t o E ffective C ancer P ain M anagement (2001) (0)
- Abstract 1793: Combination treatment with a MCL1 Inhibitor AZD5991 overcomes resistance to MEK inhibitor in TNBC cells (2022) (0)
- Co-targeting PI3K and ras pathways in trastuzumab resistance. (2013) (0)
- Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis (2019) (0)
- Abstract P2-01-04: The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer (2018) (0)
- Abstract PD11-07: Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer (2022) (0)
- Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer (2017) (0)
- Neratinib Ef fi cacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonampli fi ed Metastatic Breast Cancer (2017) (0)
- Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS (2022) (0)
- INDEX to INTEGRATIVE CANCER THERAPIES (2004) (0)
- Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Proliferative markers in predicting recurrence risk of breast cancer (2017) (0)
- Improving Chronic Ankle Instability Patient Reported Outcomes with Sensory-Targeted Ankle Rehabilitation Strategies (0)
- ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing (2022) (0)
- Personalizing Management of Patients at Elevated Breast Cancer Risk: Where do we Start? (2014) (0)
- Abstract P6-10-08: Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers (2023) (0)
- Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers (2018) (0)
- Complementary and Alternative Medicine in Breast Cancer (2001) (0)
- Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer (2020) (0)
- 1329 Short-term mortality in older (<66) patients with early stage breast cancer treated with adjuvant chemotherapy (2015) (0)
- Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer (2019) (0)
- Abstract P1-05-15: DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer (2023) (0)
- Immunoconjugates in the treatment of breast cancer. (2014) (0)
- Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort. (2020) (0)
- Abstract OT-34-01: Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer withPIK3CAmutation orPTENmutation (2021) (0)
- Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials (2019) (0)
- Abstract P6-01-34: Longitudinal DCE-MRI Radiomic Models for Early Prediction of Response to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer (TNBC) Patients (2023) (0)
- Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI (2023) (0)
- Abstract P6-01-06: Multi-Parametric MRI-Based Radiomics Models from Tumor and Peritumoral Regions as Potential Predictors of Treatment Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients (2023) (0)
- T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. (2016) (0)
- Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study. (2016) (0)
- New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. (2012) (0)
- Reply to Letter to the Editor on “The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer”, by G. Utkan, A. Büyükçelik, B. Yalçýn (Ann Oncol 2004; 15: 1574) (2004) (0)
- Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer (2023) (0)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (0)
- LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS (2019) (0)
- Abstract LB111: Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy (2022) (0)
- Abstract PS7-61: The Neat-HER Virtual Registry: Results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy (2021) (0)
- Abstract P4-08-01: Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer (2023) (0)
- Abstract P4-08-15: Identification of target kinases whose inhibition enhances antitumor efficacy of sacituzumab-govitecan in metastatic HER2-negative breast cancer (2023) (0)
- Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS (2023) (0)
- Abstract P3-10-16: Identification of molecules that enhance the efficacy of eribulin in TNBC and IBC cell lines (2020) (0)
- Abstract OT2-03-03: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (0)
- Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. (2023) (0)
- Comprehensive assessment of cancer stem cell like cells in prediction of pathologic complete response to preoperative dual anti–HER2 therapy for HER2–positive primary breast cancer. (2017) (0)
- Abstract 897: PEA-15 regulates epithelial-mesenchymal transition and invasive behavior through its phosphorylation in triple-negative breast cancer (2017) (0)
- Integrative Tumor Board: Metastatic Breast Cancer (2006) (0)
- Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2020) (0)
- Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial (2018) (0)
- Abstract P5-08-27: Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry (2017) (0)
- Abstract P5-08-13: NDRG1 expression is an independent prognostic factor in inflammatory breast cancer (2022) (0)
- Abstract 1897: Mechanism of MEK inhibitor resistance in triple negative breast cancer (2020) (0)
- Erratum. Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer. (2015) (0)
- Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis (2023) (0)
- 315P Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results (2021) (0)
- Abstract ES9-2: Understanding the Role of Botanicals in the Management of Breast Cancer (2010) (0)
- Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
- Abstract P6-05-45: Providing Educational Resources during the Pandemic for Advanced Breast Cancer Patients (2023) (0)
- Abstract B10: Fasting blood glucose and bone mineral density in Latina breast cancer survivors (2015) (0)
- Abstract P4-02-26: Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2 (2023) (0)
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. (2023) (0)
- Efficacy a nd S afety o f T rastuzumab a s a S ingle A gent i n First-Line T reatment o f HER2 -Overexpressing M etastatic Breast C ancer (2011) (0)
- Abstract P5-02-39: Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis (2023) (0)
- Abstract 2698: ERα and NAMPT crosstalk at enhancers drives Fulvestrant resistance in metastatic breast tumors (2022) (0)
- Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy (2019) (0)
- Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer (2022) (0)
- 275PFirst-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry (2017) (0)
- Faculty Opinions recommendation of HER2 and response to paclitaxel in node-positive breast cancer. (2007) (0)
- A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. (2016) (0)
- Implementation and uptake of an interactive virtual online tumor board across NCI-Cancer Centers. (2019) (0)
- Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL (2015) (0)
- Abstract P2-02-04: MRI Findings and Outcomes in an Underserved Breast Cancer Population Screened withBRCATesting (2010) (0)
- Vitamin D deficiency in older cancer patients with solid tumors, effect on overall survival. (2018) (0)
- Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer (2020) (0)
- A Flurry of Guidelines for breast Cancer management (2014) (0)
- Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression (2022) (0)
- Abstract P4-11-08: A Pilot Safety and Feasibility Study of Concurrent Capecitabine and External Beam Irradiation in the Adjuvant Treatment of High Risk Early Stage Breast Cancer (2010) (0)
- Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. (2022) (0)
- ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors (2022) (0)
- ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2017) (0)
- Abstract PS4-07: Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference (2021) (0)
- Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study (2021) (0)
- Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry. (2017) (0)
- Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. (2023) (0)
- Abstract P4-02-05: Predictors of MRI detection of occult lesions in newly diagnosed breast cancer (2016) (0)
- A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. (2023) (0)
- Associations between fatigue and cellular metabolism in breast cancer patients: A longitudinal study (2022) (0)
- Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT) (2021) (0)
- Abstract P5-11-18: Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial (2017) (0)
- Highlights From the 13th Annual International Congress on the Future of Breast Cancer (2015) (0)
- Value-Based Breast Cancer Care (2016) (0)
- PS 17-28 THE EFFECT OF A COMBINED AEROBIC AND RESISTANCE EXERCISE TRAINING ON BLOOD PRESSURE IN BREAST CANCER SURVIVORS WITH HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL (2016) (0)
- Metastatic Breast Cancer : Underlying Rationale and Results of Clinical Trials Capecitabine in Combination with Novel Targeted Agents in the Management of (2007) (0)
- Reply to “Letter to the Editor on ‘Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial”’, by A. M. Westermann doi:10.1093/annonc/mdi072 (2005) (0)
- Abstract HER2-04: HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0 (2023) (0)
- The Relationship Between Psychological Distress, Fatigue, and Body Composition in Hodgkin’s Lymphoma Survivors (2016) (0)
- Abstract P3-02-04: Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy (2023) (0)
- Abstract 2736: Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin (2022) (0)
- Muscular Strength and Bone Mineral Density in Breast Cancer Survivors: 2304 Board #51 May 29, 11 (2015) (0)
- Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1 (2023) (0)
- Value of routine staging imaging studies (RSIS) for patients with stage III breast cancer (BC). (2014) (0)
- Self-Reported Upper Extremity Function and Estimated 1-Repetition Maximum in Sedentary Breast Cancer Survivors.: 542 Board #7 May 28, 1 (2014) (0)
- Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens (2022) (0)
- Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
- Abstract P4-03-22: Linking Internal Medicine Care to Metastatic Breast Cancer Patients for Success: LIMBS (2023) (0)
- Reply to E. Parkin et al. (2018) (0)
- Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells (2020) (0)
- The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Author's reply (2004) (0)
- A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy (2022) (0)
- Abstract P5-13-01: Effects of a 16-week combined aerobic and resistance exercise intervention on metabolic syndrome in overweight/Obese Hispanic breast cancer survivors (2018) (0)
- 5088 POSTER Assessment of Burden of Illness in Women With HER2+ Metastatic Breast Cancer: Findings From a Community Web-based Survey (2011) (0)
- Abstract P1-04-07: Isolation and expression profiling of EpCAM-negative circulating tumor cells in human and xenograft models of breast cancer (2013) (0)
- Abstract P3-06-01: Clonal evolution and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy (2019) (0)
- Abstract OT2-07-10: ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) (2018) (0)
- Abstract OT-09-01: An open-label, multicenter study evaluating the safety of lasofoxifene in combination with abemaciclib for the treatment of pre and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and have anESR1mutation (2021) (0)
- Abstract P3-07-01: Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer (2017) (0)
- Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. (2015) (0)
- Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer (2021) (0)
- Abstract OT3-2-05: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2015) (0)
- 191PPathological proliferation score to predict genomic risk categories in early stage breast cancer (2017) (0)
- Relationship Between Quality of Life and Lean Body Mass in Latina Breast Cancer Survivors: 835 Board #250 May 28, 2 (2014) (0)
- The use of medical resources at the end-of-life among gynecologic cancer patients at an urban, public hospital (2013) (0)
- Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC). (2021) (0)
- Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan (2022) (0)
- 436 Renal safety of intravenous ibandronate with short infusion times (2003) (0)
- Abstract P3-01-06: Decorin-mediated suppression of tumorigenesis and skin invasion in inflammatory breast cancer via inhibition of the E-cadherin/EGFR axis (2020) (0)
- Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. (2023) (0)
- Abstract 4346: TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients (2023) (0)
- Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Antitumor Activity of KW-2450 against Triple- NegativeBreastCancerbyInhibitingAuroraAand (2015) (0)
- Abstract C122: Ethnicity as a moderator of the effects of aerobic and resistance exercise on metabolic syndrome in breast cancer survivors (2020) (0)
- The Neat-HER virtual registry: Updated results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy. (2021) (0)
- Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 2006 - Moderate risk of recurrence and poor long-term survival in patients with stage I, lymph node-negative, HER2-overexpressing breast cancer (2007) (0)
- Point-Counterpoint: Soy Intake for Breast Cancer Patients (2002) (0)
- Abstract 2338: CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint (2017) (0)
- A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays: Charpin C, Secq V, Giusiano S, et al (Hôpital Nord, Université de la Méditerranée (Aix Marseille II), France; et al) Int J Cancer 124:2124-2134, 2009§ (2010) (0)
- HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer (2019) (0)
- Intravenous and oral ibandronate provide long-term relief from bone pain in metastatic breast cancer (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Debu Tripathy?
Debu Tripathy is affiliated with the following schools:
- University of California, Berkeley
- MD Anderson Cancer Center
- California Institute of Technology
- University of Alberta
- University of Southern California
- Loyola University Chicago
- National Taiwan University
- University of California, San Francisco
- University of Antwerp
- California South Bay University
- Stanford University
- University of Miami
- University of Texas Southwestern Medical Center
- University of Cambridge
- University of Pennsylvania
